Richard Burr: “Would you provide that metrics for the Committee?”

I question whether the agreements both passed and proposed reflect a good deal for patients they are designed to serve.

I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.

He is an embarrassment on any day that ends in Y.

I went through a litany in my opening statements of the deficiencies in what FDA committed to and what they missed.